Zostavax (Zoster Vaccine Live) Products Liability Litigation
The scientific causation is based on the understanding that Zostavax contains a live attenuated varicella-zoster virus, which in rare cases can cause infection or reactivate, leading to shingles, neurological injuries, or fatal disseminated infections. FDA warnings and scientific literature corroborate that the live virus can, in susceptible individuals, disseminate or cause severe adverse effects, supporting the causation theory in litigation.
826
Pending actions
2,665
Total actions filed
Active
Status
08/02/2018
Established
Who qualifies
Plaintiffs must demonstrate injuries caused by exposure to the live virus component of Zostavax, with injury onset typically within weeks to months post-vaccination. Cases involve allegations of adverse effects such as shingles, neuralgia, vision loss, neurological damage, or death. The vaccine is administered as a single dose, and the injury must be linked causally to the vaccine, often within a 12-month period.
Products involved
- Zostavax (Zoster Vaccine Live)
Alleged injuries
- Shingles (Herpes Zoster)
- Post-Herpetic Neuralgia
- Blindness and Visual Impairment
- Neurological Injuries
- Death
Bellwether trials
As of March 2026, there are no publicly available updates on scheduled bellwether trials or recent verdicts in MDL-2848. The litigation is ongoing, with active pre-trial proceedings including expert declarations and case management orders, but no recent trial outcomes have been publicly reported.
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
